Bolnick Jay M, Velazquez Maria D, Gonzalez Jose L, Rappaport Valerie J, McIlwain-Dunivan Gena, Rayburn William F
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, School of Medicine, University of New Mexico, Albuquerque, NM, Mexico 87131-0001, USA.
Am J Obstet Gynecol. 2004 Jan;190(1):124-8. doi: 10.1016/s0002-9378(03)00952-9.
The purpose of this study was to compare the efficacy of two protocols for active management of labor at term in the presence of an unfavorable cervix.
Pregnancies that underwent labor induction at > or =37 weeks of gestation with an unfavorable cervix (Bishop score, < or =6) were randomly assigned to receive vaginally either a single dose of sustained-release dinoprostone (Cervidil) with concurrent low-dose oxytocin or multidosing of misoprostol (25 microg every 4 hours) followed by high-dose oxytocin. The primary outcome was the time interval from induction to vaginal delivery. Other parameters included excess uterine activity and cesarean delivery rates.
A total of 151 patients (dinoprostone, 74 patients; misoprostol, 77 patients) were enrolled. The mean time from the initiation of induction to vaginal delivery was the same in the dinoprostone and misoprostol groups (15.7 hours; 95% CI, 13.7-17.7 hours vs 16.0 hours; 95% CI, 14.1-17.8 hours; P=.34), regardless of parity. The dinoprostone and misoprostol groups did not differ statistically in the percent of patients who were delivered vaginally by 12 hours (36.2% vs 29.7%), 18 hours (63.8% vs 56.3%), and 24 hours (81.0% vs 81.3%). Excess uterine activity was not more common in either group, and hyperstimulation syndrome was absent in all cases. Primary cesarean delivery rates were similar (dinoprostone, 21.6%; misoprostol, 16.9%; relative risk, 1.3; 95% CI, 0.7-2.5), with a failed induction that occurred in one case in each group.
Sustained-release dinoprostone with concurrent low-dose oxytocin and intermittent misoprostol with delayed high-dose oxytocin are effective alternatives for active management of labor with an unfavorable cervix.
本研究旨在比较两种在宫颈条件不佳情况下足月产积极处理方案的疗效。
妊娠≥37周且宫颈条件不佳(Bishop评分≤6分)并接受引产的孕妇被随机分配,经阴道接受单剂量缓释地诺前列酮(欣普贝生)并同时使用低剂量缩宫素,或多次使用米索前列醇(每4小时25微克)随后使用高剂量缩宫素。主要结局是从引产到阴道分娩的时间间隔。其他参数包括子宫活动过度及剖宫产率。
共纳入151例患者(地诺前列酮组74例;米索前列醇组77例)。地诺前列酮组和米索前列醇组从引产开始至阴道分娩的平均时间相同(15.7小时;95%可信区间,13.7 - 17.7小时 vs 16.0小时;9�%可信区间,14.1 - 17.8小时;P = 0.34),无论产次如何。地诺前列酮组和米索前列醇组在12小时(36.2%对29.7%)、18小时(63.8%对56.3%)和24小时(81.0%对81.3%)内阴道分娩的患者百分比在统计学上无差异。两组中子宫活动过度均不常见,且所有病例均未出现子宫过度刺激综合征。初次剖宫产率相似(地诺前列酮组,21.6%;米索前列醇组,16.9%;相对危险度,1.3;95%可信区间,0.7 - 2.5),每组各有1例引产失败。
单剂量缓释地诺前列酮并同时使用低剂量缩宫素以及间断使用米索前列醇并延迟使用高剂量缩宫素是宫颈条件不佳时产程积极处理的有效替代方案。